A controversy has emerged as Orchid Health, a U.S. company, announces its plan to offer fertility clinics a service that sequences the whole genomes of embryos conceived through in vitro fertilization (IVF). The new test, costing $2500 per embryo, goes beyond traditional single-gene mutation screening to include extensive analysis for various gene variants linked to conditions like neurodevelopmental disorders, severe obesity, and psychiatric disorders.
However, the Psychiatric Genomics Consortium (PGC), an international group of over 800 researchers, claims that Orchid is using their data improperly to generate risk estimates for psychiatric conditions. PGC asserts that the company has violated restrictions against using the data for embryo screening, emphasizing their goal to improve the lives of people with mental illness rather than preventing their births.
Orchid has not responded to requests for comment, and PGC leaders express frustration over the lack of recourse. Although PGC signals its dismay publicly, it lacks the legal standing to enforce restrictions against Orchid. The controversy highlights challenges in controlling data use post-publication and raises concerns about ethical considerations in embryo screening, particularly for complex conditions like psychiatric disorders.
Genomics researchers stress the need for a broader societal discussion about the implications of embryo screening, emphasizing the importance of responsible data use and ethical considerations in advancing genetic technologies. The debate underscores the evolving landscape of genetic testing and its potential impact on reproductive choices and societal values.
